An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2016
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 30 Oct 2016 Planned initiation date changed from 1 Mar 2016 to 1 Oct 2016.
- 26 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
- 26 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017, according to ClinicalTrials.gov record.